PIETRASANTA, DANIELA
 Distribuzione geografica
Continente #
EU - Europa 138
NA - Nord America 133
AS - Asia 97
SA - Sud America 13
Totale 381
Nazione #
US - Stati Uniti d'America 122
SG - Singapore 51
IE - Irlanda 46
DE - Germania 23
SE - Svezia 23
CN - Cina 14
HK - Hong Kong 14
BR - Brasile 12
RU - Federazione Russa 11
GB - Regno Unito 8
VN - Vietnam 7
IT - Italia 6
CZ - Repubblica Ceca 5
MX - Messico 5
CA - Canada 4
FR - Francia 4
PL - Polonia 4
AT - Austria 3
BD - Bangladesh 3
IN - India 3
FI - Finlandia 2
LT - Lituania 2
BO - Bolivia 1
DO - Repubblica Dominicana 1
ES - Italia 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
JP - Giappone 1
OM - Oman 1
TR - Turchia 1
Totale 381
Città #
Dublin 46
Singapore 18
Hong Kong 14
Ashburn 13
Beijing 9
Chandler 9
Boardman 7
Bremen 6
Lawrence 6
Los Angeles 6
Munich 6
Princeton 6
Brno 5
New York 4
Santa Clara 4
Somaglia 4
Buffalo 3
Chennai 3
Frankfurt am Main 3
Ho Chi Minh City 3
Moscow 3
Ottawa 3
Warsaw 3
Bexley 2
Chicago 2
Curitiba 2
Gunzenhausen 2
Helsinki 2
Manchester 2
Mexico City 2
Nuremberg 2
Poplar 2
Querétaro 2
Redondo Beach 2
Seattle 2
São Paulo 2
Vienna 2
Ankara 1
Anápolis 1
Atlanta 1
Brooklyn 1
Cagliari 1
Campo Alegre de Lourdes 1
Charleston 1
Chittagong 1
Denver 1
Dover 1
Falkenstein 1
Fowlerville 1
Guarulhos 1
Hanoi 1
Jacobina 1
Kingston 1
Kirkuk 1
La Paz 1
Lauro de Freitas 1
London 1
Miami 1
Monterrey 1
Orem 1
Osasco 1
Palermo 1
Phủ Lý 1
Rio de Janeiro 1
San Francisco 1
Seeb 1
Thái Bình 1
Tokyo 1
Toronto 1
Treze Tílias 1
Vilnius 1
Wroclaw 1
Totale 247
Nome #
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 68
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 60
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 59
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 59
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 58
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 52
Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real‐World” study 32
Totale 388
Categoria #
all - tutte 2.941
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.941


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202218 0 0 0 0 0 0 0 0 0 0 6 12
2022/2023107 6 6 10 0 7 7 0 12 50 1 3 5
2023/202435 4 1 3 0 3 0 10 0 0 0 3 11
2024/202582 5 0 6 1 6 4 2 18 20 2 7 11
2025/2026146 18 11 20 42 49 6 0 0 0 0 0 0
Totale 388